An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Trial ID or NCT#

NCT04433858

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

Official Title

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of at least moderate Major Depressive Disorder (MDD)
Exclusion Criteria:
  1. - Comorbidities Note for CA sites: Only Veterans are Eligible
View All Criteria
Show Less

Investigator(s)

Trisha Suppes, MD, PhD
Trisha Suppes, MD, PhD
Psychiatrist
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

View on ClinicalTrials.gov